

# Driving Performance and Delivering New Growth Opportunities

.....

Capital Markets Day London, December 5<u>, 2018</u>

**Stefan Oelrich** Head of Pharmaceuticals

**Joerg Moeller** Head of Pharmaceuticals R&D





#### Disclaimer

#### Cautionary Statements Regarding Forward-Looking Information

This presentation contains forward-looking statements. A forward-looking statement is any statement that does not relate to historical facts and events, but rather reflects Bayer's current beliefs, expectations and assumptions regarding the future. This applies, in particular, to statements in this presentation on revenue growth, including product introductions and peak sales potential, synergies, especially in relation to the acquisition and integration of Monsanto Company, portfolio adjustments, cost reduction, financial targets and earnings, cash flow generation, deleveraging and other similar statements relating to future performance, including with respect to the markets in which Bayer is active.

Although the forward-looking statements contained in this presentation are based upon what Bayer's management believes are reasonable assumptions, they necessarily involve known and unknown risks and uncertainties that could cause actual results and future events to differ materially from those anticipated in such statements. Forwardlooking statements are not guarantees of future performance and undue reliance should not be placed on them. Bayer undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws.

For more information on factors that could cause actual results and future events to differ from those anticipated in forward looking statements, please refer to the factors discussed in Bayer's public reports which are available on the Bayer website at https://www.investor.bayer.com/en/reports/annual-reports/overview/, including in the Annual Report 2017 under the caption "Report on Future Perspectives and on Opportunities and Risks".

## The Pharma Market Will Remain Attractive



#### Major market dynamics

- // Aging population
- // Accelerating pace of innovation
- // Declining R&D productivity
- // Technological disruption by breakthrough science
- // Digitalization across the value chain
- // Pressure on price for value continues to increase
- // Non-traditional new entrants


Source: IQVIA Market Prognosis Update 2018-22 incl. Radiology

## Innovative Medicines in Areas of High Unmet Medical Need



Emerging markets include Latin America, Asia (w/o Japan, Australia, New Zealand), Africa and Middle East incl. Turkey, Eastern Europe


### Continued Sales Growth and Margin Expansion



Including Radiology; Sales growth currency and portfolio adjusted; EBITDA margin before special items


- // Sales growth above industry level
- # Successfully launched and commercialized innovative products, with Xarelto and Eylea becoming blockbuster brands
- // Disciplined resource allocation
- # 2017 EBITDA margin at upper end of guidance corridor of 32-34% – achieved one year earlier than originally planned
- // Increase in R&D investment by ~€1 billion p.a. to c.17% of sales

## Key Drivers for Growth and Margin Expansion




<sup>1</sup> EBITDA margin before special items; bps: Basis points, <sup>2</sup> as percentage of sales

# Focused Leadership Strategy to Deliver Mid-term Targets and to Ensure Long-term Success



2022 targets at constant currencies, not including portfolio measures; EBITDA margin before special items; LoE: Loss of exclusivity

### Xarelto – Continued Growth of a Leading Anticoagulant




CAD: Coronary artery disease; PAD: Peripheral artery disease <sup>1</sup>Ex-US sales plus royalty from J&J as reported by Bayer

- // Most broadly indicated anticoagulant for use in venous and arterial thromboembolic conditions
- // A leading pharma brand with global sales of €5.0bn in 2017 incl. sales at Johnson & Johnson
- // New CAD/PAD indication launching in EU and the US
- // Peak sales potential: >€5.0bn1
- // Further growth driven by:
  - // Under-served patient populations
  - // Demographics
  - // Shift from warfarin
  - // New indications targeting patients currently not treated with anticoagulants

## Xarelto Demonstrates Significant Therapeutic Benefits in CAD/PAD

Potential for Changing the Current Standard of Care




- // Low overall bleeding incidence rates, although major bleeding was increased
- // No significant increase in fatal or intracranial bleeding

- // Combination of Xarelto 2.5 mg bid + aspirin 100 mg od compared to aspirin 100 mg od alone (COMPASS)
- // Significant reduction in the relative risk for the primary composite of stroke, myocardial infarction and cardiovascular death (MACE)
- // 20% improvement in net clinical benefit<sup>1</sup>
- // Provides a larger relative risk reduction than dual antiplatelet strategies
- # Xarelto is the only oral anticoagulant that is approved for the prevention of atherothrombotic events in patients with CAD or PAD

CAD: Coronary artery disease; PAD: Peripheral artery disease; MACE: Major adverse cardiovascular events; CV: Cardiovascular; RRR: Relative risk reduction <sup>1</sup> Net clinical benefit was defined as the composite of stroke, cardiovascular death, myocardial infarction, fatal bleeding or symptomatic bleeding in a critical organ

Eikelboom et al., N Engl J Med 2017; 377: 1319-1330

#### Eylea – A Leader in Retinal Diseases




- # A leader in retinal diseases with global brand sales of €5.2bn in 2017 incl. sales at Regeneron<sup>1</sup>
- # Approved for the treatment of 5 retinal diseases: wAMD, DME, BRVO, CRVO, mCNV
- // Treat and extend dosing regimen with injection intervals of up to 12 weeks or more for wAMD
- // Peak sales potential: >€2.5bn<sup>2</sup>
- // Further growth driven by:
  - // Continued generation of real-life experience in wAMD across key markets and treatment-naïve patient share gains
  - // Market expansion in DME

<sup>1</sup> Marketed by Bayer ex-US only; <sup>2</sup> As reported by Bayer wAMD: Wet age related macular degeneration; DME: Diabetic macular edema; BRVO: Branch retinal vein occlusion; CRVO: Central retinal vein occlusion, mCNV: Myopic choroidal neovascularization



57

### Larotrectinib Provides Novel Tumor-Agnostic Precision Medicine Cancer Therapy



NTRK: Neurotrophic receptor tyrosine kinase Full labeling information available at http://labeling.bayerhealthcare.com/html/products/pi/vitrakvi\_PI.pdf

- // Larotrectinib (Vitrakvi) is an oral, small molecule, highly selective inhibitor of tropomyosin receptor kinases (TRKs)
- // NTRK gene fusions can lead to cancer and are facilitating tumor growth as oncogenic drivers
- // Relevant genetic alteration is estimated to occur in about 0.5 - 1.0% of patients with solid tumors
- # FDA approved for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase gene fusion
- // Distinguished science, in-licensed from Loxo Oncology together with 2<sup>nd</sup> generation TRK inhibitor LOXO-195
- // Peak sales potential of >€750 million

BAYER

58


#### Larotrectinib Demonstrates Impressive Anti-Tumor Activity

Activity in a Wide Range of Tumors Associated with NTRK Gene Fusions

#### Maximum change in tumor size according to tumor type (RECIST) **Objective response rate** Infantile fibrosarcoma Melanoma Gastrointestinal stromal tumor Congenital mesoblastic nephroma 50 93 Soft tissue sarcoma Unknown primary Breast Colon Thyroid Bone sarcoma 40 Appendix Pancreas Assessment Salivary gland Cholangiocarcinoma Lung (N=109) 30 20 Maximum change in tumor size (%) Objective response rate 81% 10 (95% CI) (72-88%) 0 -10 Best response -20 -30 Partial response 63% // -40 -50 17% Complete response $\parallel$ -60 -70 -80 -90 -100

Lassen, U. et al., ESMO 2018 NTRK: Neurotrophic receptor tyrosine kinase; RECIST: Response evaluation criteria in solid tumors

### China is a Growth Engine for Pharma




Sales in PR China in €bn

- // Ranked among the top 5 multi-national pharma companies in China
- // Targeting sales of ~€3bn in PR China by 2022
- // Portfolio of established and innovative drugs matches China's needs
- // Strong growth of key products
- // Xarelto and Nexavar entered the National Reimbursement Drug List in 2017
- # Glucobay, Adalat, Nimotop, Bayaspirin and Ciprobay listed on China's Essential Drug List

cpa: Currency and portfolio adjusted


## Successful Track Record in Innovation



#### sGC: Soluble guanylate cyclase

#### Addressing High Unmet Medical Need and Attractive Markets

Cardiovascular Diseases are Still the "Biggest Killers", While Oncology is the Fastest Growing Market



WHO Global Health Observatory Data 2018; Decision Resources Group COPD: Chronic obstructive pulmonary disease; LRT: Lower respiratory tract; CNS: Central nervous system; CV: Cardiovascular; MS/P: Musculoskeletal/Pain

BAYER E R

#### Late-stage Pipeline with Progress in Oncology


Darolutamide met Primary Endpoint in Phase III-trial and FDA-approval of Larotrectinib

	Larotrectinib	Darolutamide	Copanlisib	Finerenone	Vericiguat
Indication	// TRK-fusion Cancer	// Prostate Cancer	// Lymphoma	// Diabetic Kidney Disease	// Chronic Heart Failure
Q Status	// FDA approved / in registration	<pre>// Phase III   (nmCRPC) // Phase III   (mHSPC)</pre>	<ul><li><i>I</i> Launched in the US</li><li><i>I</i> Phase III</li></ul>	// Phase III	<ul> <li><i>III</i> (HFrEF)</li> <li><i>Phase II</i> (HFpEF)</li> </ul>
€ Commercial Potential	// PSP >€750m	 ∥ PSP <i>≥</i> €1bn	// PSP <i>≥</i> €0.5bn	// PSP <i>≥</i> €1bn	// PSP ~€0.5bn
Clinical Completion	// Clinical program ongoing	<pre>// Completed (ARAMIS, nmCRPC) // Aug 2022e (ARASENS, mHSPC)</pre>	<pre>// May 2020e   (CHRONOS-3) // Sep 2021e   (CHRONOS-4)</pre>	<pre>// May 2020e   (FIDELIO-DKD) // Jul 2021e   (FIGARO-DKD)</pre>	<pre>// Jan 2020e   (VICTORIA, HFrEF) // Oct 2019e   (VITALY, HFpEF)</pre>

NTRK: Neurotrophic receptor tyrosine kinase; nmCRPC: Non-metastatic castration resistant prostate cancer; mHSPC: Metastatic hormone sensitive prostate cancer; HFrEF: Heart failure with reduced ejection fraction; HFpEF: Heart failure with preserved ejection fraction; PSP: Peak sales potential




### Darolutamide Significantly Extended Metastasis-free Survival in Men with Castration Resistant Prostate Cancer



- // Darolutamide is a novel non-steroidal androgen receptor antagonist in development for the treatment of prostate cancer
- // Met primary endpoint of metastasis-free survival in the ARAMIS trial in non-metastatic CRPC
- // Phase III trial in metastatic HSPC (ARASENS) ongoing
- // Potential for differentiation:
  - // Differentiated chemical structure
  - // Higher binding affinity
  - // Negligible blood-brain barrier penetration<sup>1</sup>

CRPC: Castration resistant prostate cancer; HSPC: Hormone sensitive prostate cancer; EBRT: External beam radiation therapy; LHRH: Luteinizing hormone-releasing hormone; ADT: Androgen deprivation therapy; <sup>1</sup> based on pre-clinical data In collaboration with Orion Pharmaceuticals

## Expected Launches of Key Pipeline Assets




First launch in first indication

NTRK: Neurotrophic receptor tyrosine kinase; nmCRPC: Non-metastatic castration resistant prostate cancer; mHSPC: Metastatic hormone sensitive prostate cancer; HFrEF: Heart failure with reduced ejection fraction; HFpEF: Heart failure with preserved ejection fraction, iNHL: Indolent Non-Hodgkin Lymphoma TFPI: Tissue factor pathway inhibitor; WH: Women's Health; HEM: Hematology



# Bayer Has Unique Access to Targeted Thorium Conjugates, a New Approach for Cancer Treatments



- $/\!\!/ \alpha \mbox{-radiation}$  is highly energetic and may induce DNA damage leading to cell death
- // Other than  $\beta$ -radiation,  $\alpha$ -radiation is active over a very short distance only which may increase tissue specifity
- $/\!\!/$  Targeted Thorium conjugates direct  $\alpha\mbox{-radiation}$  to tumor cells by specific antibodies
- // Thorium-227 is the only commercially viable  $\alpha$ -radionuclide for antibody targeted therapy
  - // Thorium-227 forms highly stable complexes with chelators
  - // Efficacy is independent of antibody internalisation
  - // No known mechanism for resistance to  $\alpha\mbox{-radiation}$



66

# Targeted Thorium Conjugate Platform May Have Potential in Several Oncology Settings

Project	Indication	Status	Comment
CD-22-TTC	CD-22⁺ NHL	Phase I	Significant need for new therapeutic options for the treatment of r/r NHL (DLBCL, FL)
Mesothelin-TTC	Solid tumors expressing mesothelin	Phase I	Mesothelin is overexpressed in the vast majority of pancreatic adenocarcinomas, mesotheliomas and adenocarcinomas of the lung, ovary and the stomach
PSMA-TTC	mCRPC	Phase I ready	PSMA as a predictive biomarker with high and specific overexpression in prostate cancer cells
HER2-TTC	HER2+ cancer	Pre-clinical	Potential for treatment of patients resistant/refractory to approved HER2- targeting therapies

- // Novel approach for radio-immunotherapies with local effect at the tumor
- // Tumor specifity defined by antigen/antibody selection, making TTC a flexible technology platform
- // Potential to leverage experience with Xofigo

TTC: Targeted Thorium conjugate; NHL: Non-Hodgkin's lymphoma; DLBCL: Diffuse large b-cell lymphoma; FL: Follicular lymphoma; mCRPC: Metastatic castration resistant prostate cancer; PSMA: Prostate specific membrane antigene; HER2: Human epidermal growth factor receptor 2



67

### Re-alignment of R&D-activities to Increase Sustainable R&D Productivity

#### From

- # Broad set of indications in Oncology, Cardiovascular Diseases and Gynecological Therapies
- // Focus on functional and technical expertise
- // Strong reliance on small molecules
- // Majority of assets sourced internally
- // Highly concentrated geographical footprint
- // Internally oriented resource model


#### То

- # Focus on select areas with high unmet medical need in Oncology, Cardiovascular Diseases and Gynecological Therapies
- // Focus on deep disease understanding
- # Broader mechanistic approach beyond therapeutic area focus
- // Invest in new technologies and capabilities
- // Continue to explore potentially game-changing innovations through LEAPS
- // Increased portion of R&D assets to be sourced externally in the future
- // Evolve footprint with more co-location in science hubs
- # Adapt internal cost base to free up funds for sourcing inorganic opportunities



-Ò.-

# External Innovation and Partnering are Essential Components of Success at Pharma



## First Wave of Breakthrough Investments by LEAPS



- // Biotech with Bayer and CRISPR Therapeutics as major investors
- # \$300 million over 5-6 years, associated with \$70 million equity of Bayer in CRISPR Therapeutics
- // Awarded "No. 1 Most Valuable Pharma Deal 2016" by Pharma Dive

#### TECHNOLOGIES

- // CRISPR/Cas-based DNA-editing
- Research focus:
  - I. Cardiology
  - II. Ophthalmology
- V. Ear diseases
- III. Hematology (non-malignant)
- VI. Metabolic diseases

IV. Autoimmune diseases



- // Biotech with Bayer and Versant Ventures as major investors
- // \$225 million over 4-5 years
- # BlueRock selected to Top-30 World Game Changer companies (CB Insights Game Changer Report)

#### **TECHNOLOGIES**

- # Best-in-class induced pluripotent stem cell therapies using an industryleading platform
- // Vision is to cure diseases with significant cell loss and diminished selfrepair potential
- // (Initial) research focus on:
  - I. Cardiology (heart muscle regeneration after MI or with HF)
  - II. Neurology (Parkinson's disease)

MI: Myocardial infarction; HF: Heart failure

/// Bayer Capital Markets Day /// London, December 5, 2018

# Further Growth in Sales and Profitability

Pharma	2018e	Indicative Guidance 2019	Target 2022
Sales/Sales growth	~€16.8bn	~4%	CAGR 4-5%
EBITDA/EBITDA margin	~€5.6bn	~34%	>35%

2022 targets at constant currencies, not including portfolio measures EBITDA / EBITDA margin based on EBITDA before special items

## We Are Confident for Pharma Also Beyond 2022



## Key Takeaways

Driving Performance and Delivering New Growth Opportunities



LoE: Loss of exclusivity; nmCRPC: Non-metastatic castration resistant prostate cancer

# Experienced Pharmaceuticals Executive Leadership Team



<sup>1</sup> Stefan Oelrich will additionally take over the lead for PH Strategic Marketing on an interim basis; <sup>2</sup> Additional role as Chief Medical Officer for Bayer AG



# Capital Markets Day Pharmaceuticals

Appendix



#### Our Pipeline Contains ~50 Projects in Clinical Development

#### Phase I (26)

Cancer / TRK Inhibitor (LOXO-195)

Cancer / Rogaratinib (pan-FGFR Inhibitor) Cancer / PTEFb Inhibitor Cancer / mIDH1 Inhibitor Cancer / ATR Inhibitor Cancer / DHODH Inhibitor Cancer / Regorafenib\* (multi-Kinase Inhibitor) Cancer / Anetumab Ravtansine (Mesothelin-ADC) Cancer / Lupartumab Amadotin (C4.4a-ADC) Cancer / CD22-Targeted Thorium Conjugate Cancer / MSLN-Targeted Thorium Conjugate Cancer / CEACAM6 fb Antibody Cancer / ILDR2 fb Antibody Heart Failure / Vasopressin Receptor Antagonist Chronic Kidney Disease / sGC Activator 1 Chron. Kidney Disease / Vasopressin V1a Receptor Antag. Pulmonary Hypertension / sGC Activator 2 Anti-coagulation / FXIa Inhibitor Endometriosis / P2X3 Antagonist 1 Endometriosis / Persist. Chron. Cough / P2X3 Antagonist 2 Endometriosis / P2X4 Antagonist Endometriosis / Rheumatoid Arthritis / IRAK4 Inhibitor 1 Hemophilia / FVIII Gene Therapy Acute Respiratory Distress Syndrome / sGC Activator 3 Acute Respiratory Distress Syndrome / PEG-ADM Inhale Rheumatoid Arthritis / IRAK4 Inhibitor 2

#### Phase II (13) Cancer / Radium-223 (a-Emitter) Urothelial Cancer / Rogaratinib (pan-FGFR Inhibitor) Thrombosis / FXI Antisense (IONIS) Thrombosis / anti-FXIa Antibody Peripheral Artery Disease / AR-Alpha 2c Receptor Antagonist Heart Failure preserved EF / Vericiguat (sGC Stimulator) Heart Failure / Fulacimstat (Chymase Inhibitor) Chronic Kidney Disease / Fulacimstat Endometriosis / Vilaprisan (S-PR Modulator) Contraception / Combi IUS: LNG (Progestin) + Indomethacin (NSAID) Hemophilia / anti-TFPI-Antibody Obstructive Sleep Apnea / TASK Channel-Blocker Persistent Chronic Cough / P2X3 Antagonist 1

#### Phase III (11)

Prostate Cancer (nmCRPC) / Darolutamide (AR Antagonist) Prostate Cancer (mHSPC) / Darolutamide Non-Hodgkin Lymphoma / Copanlisib (PI3K Inhibitor) Peripheral Artery Disease / Rivaroxaban (FXa Inhibitor) Chronic Heart Failure and Coronary Artery Dis. / Rivaroxaban Medically III / Rivaroxaban Venous Thromboembolism in Children / Rivaroxaban Heart Failure reduced EF / Vericiguat (sGC Stimulator) Diabetic Kidney Disease / Finerenone (nst MR Antagonist) Renal Anemia / Molidustat (HIF-PH Inhibitor) Sympt. Uterine Fibroids / Vilaprisan (S-PR Modulator)


Oncology Cardiovascular & Kidney Diseases Gynecology Hemophilia Others

/// Bayer Capital Markets Day /// London, December 5, 2018

#### BAYER E R

76

# Finerenone May Reduce the Risk of CV-mortality and the Progression of Kidney Disease in Patients with Diabetic Kidney Disease




Dose dependent reduction of proteinuria by finerenone when added to RAS blocker therapy in patients with DKD

- // Finerenone is a novel non-steroidal MRA that has greater receptor selectivity and better receptor affinity than existing MRAs (e.g. spironolactone, eplerenone)
- // Addressing high unmet medical need
- // Two phase III trials in diabetic kidney disease underway: FIDELIO DKD (CV study) and FIGARO DKD (renal study)
- // Potential for differentiation:
  - // First-in-class MRA for treatment of DKD
  - // Non-steroidal structure, no interaction with steroid hormone receptors compared to existing MRAs
  - // Low risk of hyperkalemia which prohibits the use of marketed MRAs in DKD

MRA: Mineralocorticoid receptor antagonist; RAS: Renin-angiotensin system; CV: Cardiovascular; DKD: Diabetic kidney disease; UACR: Urinary albumin-creatinine ratio <sup>1</sup> Bakris, G.L. et al., JAMA 2015; 314:884-894.

#### Vericiguat is a Potentially New Treatment Option on Top of Standard of Care for Patients with Heart Failure



#### Dose-response relationship between vericiguat dose and reduction in NT-proBNP, a surrogate marker for cardiac function

sGC: Soluble guanylate cyclase; NO: Nitric oxide; cGMP: Cyclic guanosinmonophosphate; OD: Once daily; PLA: Placebo; NT-proBNP: N-terminal prohormone of brain natriuretic peptide <sup>1</sup> Gheorghiade, M. et al: JAMA 2015; 314: 2251-2262

- // First-in-class, direct sGC stimulator addressing the NO-sGC-cGMP pathway, a relevant mechanism in heart failure
- # Heart failure is still associated with significant mortality risk despite the availability of new therapeutic options
- // Potential for differentiation:
  - // New mode of action to be positioned on top of standard of care
  - // OD dosing and overall favorable safety and tolerability profile
- // Development in collaboration with Merck & Co.



#### BAYER E R

78

## Copanlisib is a Differentiated PI3K-inhibitor for the Treatment of Lymphoma

#### Key phase II data (CHRONOS-1)<sup>1</sup>

Overall response rate in patients with follicular B-cell non-Hodgkin's lymphoma who had relapsed disease following at least two prior treatments:

n=104	Copanlisib		
Overall response rate	59%		
// Complete response	14%		
// Partial response	44%		

Copanlisib had a favorable safety profile with a low rate of severe toxicities overall.

- // Phosphatidylinositol-3-kinase (PI3K) inhibitor blocking cellular signal transduction processes crucial for cancer progression
- // In development for various forms of lymphoma
- // Potential for differentiation:
  - // Inhibits different isoforms of PI3K
  - // Intravenous administration, thus lower propensity for serious gastrointestinal toxicity
  - // Intermittent once weekly dosing
- // Launched in the US in 2017 for the treatment of relapsed follicular lymphoma. Registration granted under accelerated FDA approval based on phase II data

<sup>1</sup> Dryling M. et al.: Blood 2017; 130: 2777



# Driving Performance and Delivering New Growth Opportunities

.....

Capital Markets Day London, December 5<u>, 2018</u>

**Stefan Oelrich** Head of Pharmaceuticals

**Joerg Moeller** Head of Pharmaceuticals R&D

